NCT06743126 2026-04-13
SUPRAME
Immatics US, Inc.
Phase 3 Recruiting
Clinical Trials
12 trialsNCT06388252 2026-02-19
Electrochemotherapy Changes in Tumor Microenvironment of Cutaneous and Subcutaneous Metastases in Melanoma Patients
Institute of Oncology Ljubljana
Phase NA Enrolling by invitation
NCT05479812 2026-02-09
Dose Escalation and Expansion Study of WTX-124 as Monotherapy and in Combination With Pembrolizumab (Pembro) in Patients With Selected Advanced or Metastatic Solid Tumors
Werewolf Therapeutics, Inc.
Phase 1 Active not recruiting
NCT04620603 2025-11-06
Low-Dose-Rate Brachytherapy Combined With Immune Checkpoint Inhibition in Cancer
Case Comprehensive Cancer Center
Phase 1 Active not recruiting
NCT05585320 2025-09-02
A Phase 1/2a Study of IMM-1-104 in Participants With Advanced or Metastatic Solid Tumors
Immuneering Corporation
Phase 1/2 Active not recruiting
NCT06208124 2025-05-28
A Study of IMM-6-415 in RAS/RAF Mutant Solid Tumors
Immuneering Corporation
Phase 1/2 Completed
NCT01748448 2025-02-17
ViDMe
Universitaire Ziekenhuizen KU Leuven
Phase 3 Completed
NCT06767332 2025-01-09
FAME
Leiden University Medical Center
Phase NA Recruiting
NCT02308553 2020-10-14
NIPAWILMA
University Hospital, Essen
Phase 1/2 Completed
NCT02309632 2019-07-29
Pancreatic Cancer Screening of High-Risk Individuals in Arkansas
University of Arkansas
Phase NA Withdrawn
NCT03541148 2018-05-30
Evaluation of Oncoxin-Viusid® in Cutaneous Melanoma
Catalysis SL
Phase 2 Completed
NCT00816374 2014-05-16
Tailored Intervention for Melanoma Patient's Families
Fox Chase Cancer Center
Phase NA Completed